Elite controllers or suppressors are untreated human im-munodeficiency virus type 1 (HIV-1)–infected patients who maintain undetectable viral loads. In this study, we show that most elite suppressors do not experience significant changes in T cell counts over a 10-year period. Interestingly, treatment of an elite suppressor with highly active antiret-roviral therapy (HAART) led to a marked decrease in im-mune activation. Although CD4+ T cell depletion is the hallmark of progressive human immunodeficiency virus type 1 (HIV-1) infection, the mechanisms involved in this depletion are still not fully un-derstood. Some studies have shown that the HIV-1 load cor-relates with the rate of decay of CD4+ T cells [1, 2], whereas others have shown a st...
A small fraction of HIV-infected individuals (<1%), referred to as elite controllers (EC), are ab...
HIV-1 infection is characterized by generalized deregulation of the immune system, resulting in incr...
We longitudinally evaluated HIV-specific T-cell immunity after discontinuation of highly active anti...
Abstract Background Elite controllers (EC) are a rare subset of HIV infected individuals who control...
Elite controllers suppress human immunodeficiency virus (HIV) viremia to below the limit of detectio...
HIV-1 infection is typically characterized by robust viral replication and progressive CD4+ T cell d...
Human immunodeficiency virus type-1 (HIV-1) elite controllers (ELCs) represent a unique population t...
Human immunodeficiency virus type 1 (HIV-1)-infected subjects treated early after infection have pre...
therapy (HAART), recovery of CD4T cell counts can be impaired. We investigated whether this impairme...
HAART in HIV-1-infected individuals has a broad spectrum of clinical outcomes. In the majority of pa...
HIV-1 elite controllers (EC) maintain undetectable viral loads (VL) in the absence of antiretroviral...
Despite variability, the majority of HIV-1-infected individuals progress to AIDS characterized by hi...
Some patients infected with human immunode®ciency virus (HIV) who are experiencing antiretroviral tr...
International audienceHIV controllers are rare individuals who spontaneously control HIV replication...
HIV-1 elite controllers (EC) maintain undetectable viral loads (VL) in the absence of antiretroviral...
A small fraction of HIV-infected individuals (<1%), referred to as elite controllers (EC), are ab...
HIV-1 infection is characterized by generalized deregulation of the immune system, resulting in incr...
We longitudinally evaluated HIV-specific T-cell immunity after discontinuation of highly active anti...
Abstract Background Elite controllers (EC) are a rare subset of HIV infected individuals who control...
Elite controllers suppress human immunodeficiency virus (HIV) viremia to below the limit of detectio...
HIV-1 infection is typically characterized by robust viral replication and progressive CD4+ T cell d...
Human immunodeficiency virus type-1 (HIV-1) elite controllers (ELCs) represent a unique population t...
Human immunodeficiency virus type 1 (HIV-1)-infected subjects treated early after infection have pre...
therapy (HAART), recovery of CD4T cell counts can be impaired. We investigated whether this impairme...
HAART in HIV-1-infected individuals has a broad spectrum of clinical outcomes. In the majority of pa...
HIV-1 elite controllers (EC) maintain undetectable viral loads (VL) in the absence of antiretroviral...
Despite variability, the majority of HIV-1-infected individuals progress to AIDS characterized by hi...
Some patients infected with human immunode®ciency virus (HIV) who are experiencing antiretroviral tr...
International audienceHIV controllers are rare individuals who spontaneously control HIV replication...
HIV-1 elite controllers (EC) maintain undetectable viral loads (VL) in the absence of antiretroviral...
A small fraction of HIV-infected individuals (<1%), referred to as elite controllers (EC), are ab...
HIV-1 infection is characterized by generalized deregulation of the immune system, resulting in incr...
We longitudinally evaluated HIV-specific T-cell immunity after discontinuation of highly active anti...